As for β1-AR, chronic treatment with xamoterol, a selective, functionally biased, partial agonist of β1-AR, was effective to ameliorate cognitive deficits and reduce neuroinflammation and Aβ/tau pathologies in transgenic mouse models of AD [85, 86]. The gene discussed is MAPT; the disease is Alzheimer disease.